Oncopeptides
OverviewSuggest Edit
Oncopeptides is a clinical development pharmaceutical company. It develops anti-cancer drugs. The Company has created Ygalo, a cytotoxic therapy that is in late-stage development use for the treatment of multiple myeloma.
| Type | Public | |
| Founded | 2000 | |
| HQ | Stockholm, SE | Map |
| Website | oncopeptides.se |
Recent NewsAll News
- With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA
- Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma
- Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included
- Oncopeptides AB: Interim Report Q2 2020
Key People/Management at Oncopeptides
Brian Stuglik
Board Member
Cecilia Daun Wennborg
Board Member
Anders Martin-Löf
Chief Financial Officer
Paula Boultbee
Chief Commercial Officer
Jarl Ulf Jungnelius
Board Member
Jennifer Jackson
Board Member
Oncopeptides Office Locations
Oncopeptides has offices in Stockholm, Los Altos, Mountain View and Waltham
Stockholm, SE (HQ)
46 Luntmakargatan
Stockholm, SE
Tändstickspalatset, Västra Trädgårdsgatan 15
Los Altos, US
4940 El Camino Real #100
Mountain View, US
444 Castro St
Waltham, US
200 5th Ave #1030
Oncopeptides Financials and Metrics
Oncopeptides Revenue
Market capitalization (19-Nov-2020) | 11.4b |
Closing stock price (19-Nov-2020) | 168.0 |
Oncopeptides's current market capitalization is kr11.4 b.
Oncopeptides Cybersecurity Score
Oncopeptides Online and Social Media Presence
Oncopeptides's Trends
Oncopeptides News and Updates
October 12, 2020
With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA
STOCKHOLM, Oct. 12, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has informed the European Medicines Agency, EMA, about its intention to submit an application for a conditional marketing authorization of melflufen (INN melphalan...
October 01, 2020
Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma
STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is formally open. Melflufen (INN melphalan flufenamide), is currently being evaluated in several...
September 04, 2020
Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included
STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the last patient has been successfully enrolled in the pivotal phase 3 study OCEAN in relapsed refractory multiple myeloma (RRMM). The original enrollment target of 450 patients...
August 26, 2020
Oncopeptides AB: Interim Report Q2 2020
STOCKHOLM, Aug. 26, 2020 /PRNewswire/ -- Summary Financial overview April 1 - June 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 401.0 M (loss: 171.9) Loss per share, before and after dilution, was SEK 6.79 (loss: 3.52) On June 30 cash and cash equivalents...
August 07, 2020
Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study
STOCKHOLM, Aug. 7, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the first patient has been enrolled in the Immunoglobulin Light Chain (AL) amyloidosis (OP-201) study. This open-label, phase 1/2 study of melflufen and dexamethasone for patients...
August 04, 2020
Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma
STOCKHOLM, Aug. 4, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announced that the first patient has been enrolled in the phase 2 PORT study. The study, which is expected to be fully recruited in December 2020, is an open-label, randomized, cross-over study...
Oncopeptides Blogs
November 19, 2020
INTERIM REPORT Q3 2020
Summary Financial overview July 1 – September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189.8) Loss per share, before and after dilution, was SEK 5.71 (loss: 3.53) On September 30 cash and cash equivalents amounted to SEK 1,251.6 M (1,122.3) Significan…
November 05, 2020
Oncopeptides hosts a virtual capital markets day on November 30
STOCKHOLM — November 5, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company will arrange a virtual capital markets day for investors, analysts and journalists on November 30[th], 2020. The program will be published on the company´s website during the week of Novem…
November 04, 2020
Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting
STOCKHOLM — November 4, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focusing on the development of targeted therapies for difficult-to-treat hematological diseases, today announced that twelve abstracts, including one oral presentation, have been accepted for the…
October 21, 2020
Nomination committee in Oncopeptides established
STOCKHOLM — October 21, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the composition of the Nomination Committee for the Annual General Meeting 2021 has been established. The Nomination Committee consists of the following persons who together represent approximately 3…
October 19, 2020
Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform
STOCKHOLM — October 19, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), for OPD5 - a second drug candidate based on the proprietary Peptide Drug Conjuga…
October 14, 2020
Oncopeptides signs € 40 million loan agreement with the EIB
STOCKHOLM — October 14, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company has entered into a loan agreement with the European Investment Bank (EIB), granting the company access to an unsecured loan facility of up to €40 M. The loan may be used to further support…
Oncopeptides Frequently Asked Questions
When was Oncopeptides founded?
Oncopeptides was founded in 2000.
Who are Oncopeptides key executives?
Oncopeptides's key executives are Brian Stuglik, Cecilia Daun Wennborg and Anders Martin-Löf.
How many employees does Oncopeptides have?
Oncopeptides has 154 employees.
Who are Oncopeptides competitors?
Competitors of Oncopeptides include Candel Therapeutics, PCI Biotech and Propanc Biopharma.
Where is Oncopeptides headquarters?
Oncopeptides headquarters is located at 46 Luntmakargatan, Stockholm.
Where are Oncopeptides offices?
Oncopeptides has offices in Stockholm, Los Altos, Mountain View and Waltham.
How many offices does Oncopeptides have?
Oncopeptides has 5 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies